News


All series


All News

Treatment with the combination of idelalisib and ofatumumab demonstrated an improvement in objective response rates, progression-free survival, and lymph node response compared with ofatumumab alone in patients with previously treated chronic lymphocytic leukemia.

Venetoclax has demonstrated promising efficacy and a tolerable safety profile as monotherapy and in combinations for patients with relapsed/refractory multiple myeloma

Treatment with ramucirumab did not demonstrate a statistically significant improvement in overall survival compared with placebo for patients with hepatocellular carcinoma who had received prior treatment with sorafenib.

This case-based program is designed to educate healthcare providers on the optimal management of patients with ER+/HER2– MBC, with the goal of improving patient outcomes including quality of life and survival.

Researchers at the Wistar Institute Cancer Center have discovered a new potential circulating biomarker for non–small cell lung cancer. It is a cancer testis antigen expressed by a cancer/testis gene called AKAP4. The exciting prospect this heralds is the development of an accurate, quick blood test for early-stage NSCLC.

The next-generation ALK inhibitor alectinib has demonstrated robust objective response rates (ORR) in patients with ALK-positive non–small cell lung cancer, including those with central nervous system metastases.